



INTERNATIONAL GENERIC AND
BIOSIMILAR MEDICINES ASSOCIATION

Info: info@igbamedicines.org

IGBA's CEO Advisory Committee Meets with WIPO Director General Daren Tang

For immediate release
Geneva, 10 October 2023

The International Generic and Biosimilar Medicines Association's (IGBA) [CEO Advisory Committee](#) held an exchange with Mr. Daren Tang, Director General of the World Intellectual Property Organization (WIPO). This was the first opportunity for Mr. Tang to engage in a direct dialogue with IGBA CEO Advisory Committee Members.

"The generic and biosimilar medicines industry supplies an estimated 80% of all medicines globally, and is therefore absolutely critical to ensuring safe and affordable medicines are available to patients around the world. A balanced IP regime and timely market access are consequently paramount", said David Gaugh, Interim President and CEO of the Accessible Medicines Association (AAM) and IGBA Chair during his introductory remarks.

During the exchange, Mr. Richard Saynor, Chief Executive Officer of Sandoz and Chair of the CEO Advisory Committee, emphasized the importance of the sector and expressed IGBA's openness to cooperation with WIPO. *"This exchange is a first step towards a long-term dialogue with Mr. Tang and the WIPO on core issues at the intersection of intellectual property, health, and trade,"* concluded Saynor.

IGBA's CEO Advisory Committee was established in February 2022 as a forum for generic and biosimilar medicines industry leaders to discuss broad strategic issues, and to engage and position the industry on a range of critical policy matters.

For more information:

- [IGBA establishes a CEO Advisory Committee](#)
- [IGBA's Newly Launched CEO Advisory Committee Holds Inaugural Meeting with WTO Director General](#)
- [IGBA's CEO Advisory Committee Meets with WHO Director General and WHO Leadership](#)

About us: The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients' access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org.